It was one of the first new drugs approved for acute myeloid leukemia in years. But more than a year after the Food and Drug Administration gave it the green light, and despite impressive clinical ...

Jazz Pharmaceuticals has a couple of new selling points—and a bigger supporting salesforce—for its leukemia drug Vyxeos, so why did sales fall so far short of expectations in the third quarter?

A phase 3 study showed improved survival rates for patients with high-risk, secondary AML who took Vyxeos. When compared with cytarabine and daunorubicin (7+3), Vyxeos (CPX-351) reduced risk of death ...

More people with AML who were treated with Vyxeos were moved to transplant than those treated with a standard chemotherapy regimen, according to recent findings. After treatment with Vyxeos (CPX-351), ...

Abecma cleared as first cell-based gene therapy for multiple myeloma in adults Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) has been approved for treating relapsed or refractory multiple ...

With its $1.5 billion buyout of Celator Pharmaceuticals Inc. to take ownership of Vyxeos for high-risk (secondary) acute myeloid leukemia (AML), Jazz Pharmaceuticals plc is not done exploring the ...

The approval was supported by data from a study in 309 patients (60-75 years of age) with newly diagnosed t-AML or AML-MRC who were randomized to either Vyxeos or daunorubicin and cytarabine ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The FDA has expanded the approval of Vyxeos® (daunorubicin and cytarabine; Jazz Pharmaceuticals) to include the treatment of patients aged 1 year and older with newly-diagnosed therapy-related acute ...

Jazz Pharmaceuticals plc JAZZ announced that it has started the submission of a rolling New Drug Application (NDA) to the FDA, seeking an approval for its experimental candidate Vyxeos for the ...

Jazz Pharmaceuticals plcJAZZ announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA. The specialty ...